PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Boards of Appeal back rejection of special criteria for the novelty of purity inventions, but the Guidelines remain out of step (T 0043/18)

  • Technology: Chemistry
  • 8th September 2022
The EPO clarifies the criteria for the patentability of inventions based on the achievement of a higher chemical purity.
Block of gold cubes with one turned turquoise cube on dark blue, Evolve abstract article image.

This post is based on a previous article on IPKat.

Historically, the EPO has used a higher bar to assess the novelty for purity of compound inventions. A recent decision from the Boards of Appeal has confirmed that this approach contradicts the overarching principles of novelty. The decision in T 0043/18 particularly agreed with the 2018 decision T 1085/13 that novelty can only be destroyed by a clear and unambiguous disclosure in the prior art (G 2/88, G 2/10). Previously, purity inventions were only considered novel if a high purity could not be achieved by conventional means. The Boards of Appeal have now rejected this requirement as being more of an inventive step assessment than one of novelty. Unfortunately, the EPO Guidelines are still out of step with the Boards of Appeal. 

Legal Background: Purity as convention

In assessing the novelty of a claimed invention, the burden of proof is normally placed on the patent office (or opposing third party) to find evidence of at least an implicit disclosure of the claimed subject matter in the prior art (G 2/88, G 2/10). Historically, however, the novelty of purity was considered a special case. It was thought that the increasing purity was conventional. The burden of proof was therefore shifted to the applicant to show that all prior attempts to achieve the particular degree of purity by conventional purification processes had failed (T 0990/96, T 0219/98, T 0455/13, T 360/07).  

The special treatment of the novelty of purity was questioned in T 1085/13. This decision found that treating purity as a special case was contrary to the principle that novelty is destroyed only by a clear and unambiguous disclosure in the prior art (G 2/10). T 1085/13 was the first Board of Appeal decision to depart from the “special criteria” for purity inventions established in T 0990/96.

T 0043/18: “Decision T 1085/13 followed”

T 1085/13 left us with the question of whether other Boards of Appeal would follow suit with rejecting the treatment of the novelty of purity as a special case. The recent decision T 0043/18 shows Boards of Appeal are content to follow the reasoning in T 1085/13. 

T 0043/18 related to the opposition division decision to revoke EP 2305683 for lacking novelty. The patent related to a purer dosage form of oxycodone hydrochloride. The Opposition Division applied the “purity is conventional” criteria from T 0990/96, and found that the prior art disclosure of oxycodone hydrochloride per se had effectively made oxycodone hydrochloride available at all levels of purity. 

On appeal, the patentee cited T 1085/13, which was published after the Opposition decision. On appeal, the Board agreed with the rationale and the conclusion of T 1085/13. Particularly, the Board of Appeal found that considerations of whether increasing the purity of a compound would have been conventional were appropriate for inventive step but not for novelty. Both T 1085/13 and T 0043/18 cited the EBA decisions G 2/88 and G 2/10 establishing that novelty is destroyed only by a clear and unambiguous disclosure in the prior art. The Board of Appeal thus found the claim novel and remitted the case back to the Opposition Division. 

Final thoughts

We are not aware of any Board of Appeal decisions contradicting T 1085/13 in its rejection of the unconventionality novelty criteria for purity established in T 0990/96. As well as T 0043/18, the reasoning of T 1085/13 was supported in T 1914/15. 

The EPO Guidelines for Examination, on the other hand, are still out of step with T 1085/13 and therefore G 2/88 and G 2/10. Nearly 3 years on from the decision in T 1085/13, the Guidelines continue to state that “A known compound is not rendered novel merely because it is available with a different degree of purity if the purity can be achieved by conventional means (see T 360/07)” (G-IV, 7). 

Given the clear reasoning in G 2/88 and G 2/10, and its application in T 1085/13 and now T 0043/18 it is unclear why the EPO Guidelines continue to cling to this language. The Guidelines historically lag behind changes in the established case law of the Boards of Appeal. Patentees and applicants of purity compound inventions can only hope Examiners and Opposition Divisions are prepared to ignore the Guidelines and to instead follow the EBA and Boards of Appeal case law. 

Further reading

Purity can be unconventional, a new position for the EPO boards of appeal (T 1085/13) (18 Feb 2019)

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice